Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

stitute, Weill Cornell Medical College, the Translational Genomics Research Institute (TGen), Karmanos Cancer Institute and Wayne State University.

"We are very excited about the results of our preclinical development, and successful clinical translation of BIND-014. The initial Phase 1 clinical efficacy and safety in advanced and metastatic cancers demonstrate promise for BIND-014 and provide strong validation for our Accurin platform to develop targeted therapeutics that accumulate at the site of disease to maximize therapeutic effect," said Jeff Hrkach, Ph.D., Senior Vice President, Technology Research and Development of BIND Biosciences. "BIND-014 represents the lead Accurin product to enter the clinic from our pipeline and is an ideal example of the power of our proprietary platform to develop targeted therapeutics."

About BIND-014

BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 NANONEX CORPORATION, a pioneer ... today announced the successful delivery and installation of ... NX-M200B, to a major Japanese manufacturing company. ... production-ready, advanced nanoimprint lithography tool that has the ... substrate sizes and types. Based on Nanonex inventions ...
(Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
(Date:5/21/2013)... The Formulate Fusion Fabric Display Kit ... marketing teams looking for a fully-functional package for their trade ... you’ll need to put together a stunning and eye-catching trade ... number of displays and accessories that can be quickly assembled ... feet in size. These components vary from kit to kit, ...
(Date:5/20/2013)... 21, 2013 Grace Century , ... “game-changing” life science and health related private equity projects, ... its International Project Team. Dergham's expertise in finance and ... depth to Grace Century as it continues to look ... Ms. Dergham holds both an under graduate degree from ...
Breaking Biology Technology:Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... Adhere to Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. ... study has shown their patients comply with Obstructive ... the industry average.Analysis performed in October 2008 looked ... testing and treatment with Positive Airway Pressure beginning ...
... 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... 2 multi-center, randomized, double-blind, placebo-controlled clinical study of ... (PAD). There was no statistical significance observed ... endpoint of the study, peak walking time (PWT), ...
... Bulletin Board: AGGX.OB) is a New York-based biotechnology company ... proteins for the discovery and development of anti-angiogenic drugs ... presented animal data at two recent scientific ... molecule candidate drug AGX51 to mitigate tumor formation and ...
Cached Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... (May 20, 2013) - A novel vaccine ... the groundbreaking research that will be unveiled at the ... (NBC). The meeting takes place Monday, May 20 - ... and Marina. , "The main goal of a ... against a pathogen that causes the disease", explained Dr. ...
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
Breaking Biology News(10 mins):Gym class reduces probability of obesity, study finds for first time 2Germ-fighting vaccine system makes great strides in delivery 2
... days shortening toward winter, many people will begin to experience ... About 6 percent of the U.S. population suffers ... begins in the fall and continues through winter. Sufferers may ... the morning. The disorder, which is not well understood, ...
... look at that cheap piece of scrap iron before you ... good use for it. Someday soon, much of the world ... engineering, recently concluded a five-year research project in which he ... million pounds of iron to detoxify pollutants in industrial wastewater. ...
... and simulation experts from Rhode Island Hospital discuss ... manuscripts appearing in the November 2008 issue of ... The articles describe how simulation centers, along with ... for dynamic, complex and unanticipated medical situations in ...
Cached Biology News:Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
Biology Products: